Humana Inc. posted stronger-than-expected second-quarter results and raised its full-year forecast, saying efforts to curb medical spending were paying off even as several rivals grapple with higher costs. Adjusted earnings for the three months ended 30 June rose to $6.27 a share, exceeding analyst estimates of about $5.9. Revenue climbed 13% from a year earlier to $32.39 billion, also ahead of projections. The insurer reported a medical cost ratio of 89.7%, essentially matching its earlier guidance of roughly 90%. On the strength of the quarter, Humana lifted its 2025 adjusted earnings outlook to about $17 a share from roughly $16.25 and said revenue should reach at least $128 billion, above the prior $126 billion–$128 billion range. The company also trimmed its expected decline in individual Medicare Advantage membership to as much as 500,000, down from an earlier projection of around 550,000. The upbeat guidance contrasts with recent cuts from other U.S. health insurers and underscores Humana’s confidence in its 2025 pricing strategy and the expansion of its CenterWell primary-care and pharmacy operations. The stock gained about 7% in pre-market trading.